Physician profile
Gina Calo
NPI 1871322354
$1,123.30
in general payments reported to CMS, 2019-2025
13 companies · $941 in 2025
The $941 reported for 2025 was more than what 96% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $182 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $203.73 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $152.57 | 2024-2025 | |
| Exact Sciences Corporation | $112.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $99.94 | 2025 | Veozah |
| Coopersurgical, INC. | $95.64 | 2024-2025 | Paragard T 380a, Sos |
| Exeltis, USA INC. | $83.26 | 2025 | Slynd |
| Organon LLC | $80.08 | 2025 | Nexplanon |
| Daiichi Sankyo INC. | $76.10 | 2024-2025 | Injectafer |
| Sage Therapeutics, LLC | $72.78 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $48.78 | 2025 | Myfembree |
| Merck Sharp & Dohme LLC | $44.58 | 2024-2025 | Gardasil 9, Gardasil |
| Pfizer INC. | $27.00 | 2025 | |
| Genzyme Corporation | $25.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Calo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.